Cover Image

Anti-prostate cancer agents /

Anti-Prostate Cancer Agents walks the readers through the anti-prostate cancer drug development pipeline from early discovery/design to clinical studies/applications. This book covers discovery/design, synthetic studies, preclinical evaluation, mechanism of action, structure-activity relationships,...

Full description

Bibliographic Details
Main Author: Chen, Qiao-Hong (Author)
Corporate Author: ScienceDirect (Online service)
Format: eBook
Language:English
Published: Amsterdam : Elsevier, 2025.
Subjects:
Antineoplastic agents > Development.
Prostate > Cancer > Prevention.
Prostate > Cancer > Chemotherapy.
Prostate > Cancer > Chimiothérapie.
Electronic books.
Online Access:Connect to the full text of this electronic book
Table of Contents:
  • Front Cover
  • ANTI-PROSTATE CANCER AGENTS
  • ANTI-PROSTATE CANCER AGENTS
  • Copyright
  • Contents
  • 1
  • Introduction: Overview of prostate cancer
  • 1.1 Definition and characteristics of prostate cancer
  • 1.1.1 Definition of prostate cancer
  • 1.1.2 Early signs and symptoms of prostate cancer
  • 1.1.3 Screening and diagnosis
  • 1.1.4 Gleason score and grade group
  • 1.1.5 Clinical stages
  • 1.2 Prostate cancer as a health concern
  • 1.3 Treatments for prostate cancer
  • 1.3.1 Current treatments for prostate cancer
  • 1.3.2 Observation or active surveillance for prostate cancer
  • 1.3.3 Radical prostatectomy
  • 1.3.4 Radiation therapy
  • 1.3.5 Hormonal therapeutics
  • 1.3.6 Cytotoxic chemotherapy
  • 1.3.7 Immunotherapy and new therapeutics
  • 1.4 Goals and objectives of the book
  • References
  • 2
  • FDA-approved therapeutics and diagnostics for prostate cancer
  • 2.1 Tabulated summary of FDA-approved therapeutics and diagnostics for prostate cancer
  • 2.2 GnRH agonists and antagonists
  • 2.2.1 Lupron depot (leuprolide acetate, GnRH agonist)
  • 2.2.1.1 Formulation and routes of administration
  • 2.2.1.2 Company
  • 2.2.1.3 Mechanism of action
  • 2.2.1.4 Efficacy data from clinical trials
  • 2.2.1.5 Major adverse reactions (no less than 5%)
  • 2.2.1.6 Chemical structure
  • 2.2.2 Eligard (leuprolide acetate)
  • 2.2.2.1 Formulation and routes of administration
  • 2.2.2.2 Company
  • 2.2.2.3 Mechanism of action
  • 2.2.2.4 Efficacy data from clinical trials
  • 2.2.2.5 Major adverse reactions (no less than 10%)
  • 2.2.2.6 Chemical structure
  • 2.2.3 Trelstar (triptorelin pamoate)
  • 2.2.3.1 Formulation and routes of administration
  • 2.2.3.2 Company
  • 2.2.3.3 Mechanism of action
  • 2.2.3.4 Efficacy data from clinical trials
  • 2.2.3.5 Major adverse reactions
  • 2.2.3.6 Chemical structure
  • 2.2.4 Zoladex (goserelin acetate implant)
  • 2.2.4.1 Formulation and routes of administration
  • 2.2.4.2 Company
  • 2.2.4.3 Mechanism of action
  • 2.2.4.4 Efficacy data from clinical trials
  • 2.2.4.5 Major adverse reactions ( 10%)
  • 2.2.4.6 Chemical structure
  • 2.2.5 Plenaxis (abarelix)
  • 2.2.5.1 Formulation and routes of administration
  • 2.2.5.2 Company
  • 2.2.5.3 Mechanism of action
  • 2.2.5.4 Efficacy data from clinical trials
  • 2.2.5.5 Major adverse reactions
  • 2.2.5.6 Chemical structure
  • 2.2.6 Firmagon (degarelix)
  • 2.2.6.1 Formulation and routes of administration
  • 2.2.6.2 Company
  • 2.2.6.3 Mechanism of action
  • 2.2.6.4 Efficacy data from clinical trials
  • 2.2.6.5 Major adverse reactions
  • 2.2.6.6 Chemical structure
  • 2.2.7 Orgovyx (relugolix)
  • 2.2.7.1 Formulation and routes of administration
  • 2.2.7.2 Company
  • 2.2.7.3 Mechanism of action
  • 2.2.7.4 Efficacy data from clinical trials
  • 2.2.7.5 Major adverse reactions
  • 2.2.7.6 Chemical structure
  • 2.2.8 CAMCEVI (leuprolide mesylate)
  • 2.2.8.1 Formulation and routes of administration
  • 2.2.8.2 Company
  • 2.2.8.3 Mechanism of action